$RGEN Cashflow Statement | Understand Stock

$RGEN

$184.69 +$8.89 (5.06%) Close

$RGEN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net Income Loss
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Inventory step-up charges
Depreciation and amortization
Amortization of debt discount and issuance costs
Inventory step-up amortization
Stock-based compensation
Deferred income taxes, net
Change in fair value of contingent consideration
Avitide, Inc.
Total change in fair value of contingent consideration

Non-cash interest income
Loss on extinguishment of debt
Loss on fixed asset abandonment
Net unrealized foreign exchange gain
Operating lease right of use asset amortization
Other adjustments and non-cash items
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable
Unbilled receivables
Inventories
Prepaid expenses and other current assets
Other noncurrent assets
Other assets
Accounts payable
Accrued liabilities
Operating lease liability
Operating lease liabilities
Noncurrent liabilities

Total cash provided by operating activities
Cash flows for investing activities
Purchase of marketable securities held to maturity
Acquisitions, net of cash acquired
Purchases of marketable securities
Maturities of marketable securities
Additions to capitalized software costs
Purchases of property, plant and equipment
Sale of property, plant and equipment
Purchase of intellectual property
Other investing activities
Total cash used in investing activities
Cash flows (for) from financing activities
Repurchase of common stock
Proceeds from issuance of 2023 Notes
Proceeds from exercise of stock options
Payment of debt issuance costs
Payment of tax withholding obligation on vesting of restricted stock
Repayment of 2019 Notes
Payment of earnout consideration
Other financing activities
Total cash (used in) provided by financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Effect of exchange rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure of cash flow information:
Income taxes paid
Interest paid
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases
Fair value of shares of common stock issued for acquisitions
Avitide, Inc.
Total fair value of shares of common stock issued for acquisitions

Fair value of earnouts related to acquisition
ARTeSYN Biosolutions Holdings Ireland Limited
Avitide, Inc.
Fair value of shares of common stock issued for contingent consideration earnouts
Acquisition date fair value of contingent consideration earnouts
Acquisition of intangible assets and issuance of financing liability
Issuance of 2023 Notes in exchange of 2019 Notes
Extinguished 2019 Notes

Comments